Drug interactions
Brexucabtagene autoleucel + Pralatrexate
Severity: Major
Brexucabtagene autoleucel and Pralatrexate: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pralatrexate is a myelosuppressive antifolate that can impair the expansion and function of CAR T cells and add to infection risk. Chemotherapy around the time of CAR T infusion can reduce the efficacy of the cell product and worsen cytopenias.
What this interaction means in plain words
Brexucabtagene autoleucel and Pralatrexate can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Brexucabtagene autoleucel belongs to Oncology; Pralatrexate belongs to Oncology.
Why it happens
Cytotoxic and myelosuppressive effects of pralatrexate may reduce CAR T-cell persistence and add to immunosuppression.
What to do
Avoid pralatrexate around leukapheresis and in the period after CAR T infusion unless clearly needed. Monitor blood counts and screen for infection.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Brexucabtagene autoleucel and Pralatrexate, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Pralatrexate
Other interactions of Brexucabtagene autoleucel
Frequently asked questions
Can I take Brexucabtagene autoleucel with Pralatrexate?
MediHelp rates the interaction as major. Brexucabtagene autoleucel and Pralatrexate can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Pralatrexate is a myelosuppressive antifolate that can impair the expansion and function of CAR T cells and add to infection risk. Chemotherapy around the time of CAR T infusion can reduce the efficacy of the cell product and worsen cytopenias.
How serious is the interaction between Brexucabtagene autoleucel and Pralatrexate?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid pralatrexate around leukapheresis and in the period after CAR T infusion unless clearly needed. Monitor blood counts and screen for infection.
What other medicines interact with Pralatrexate?
MediHelp also lists interactions of Pralatrexate with, for example, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel, Ciltacabtagene autoleucel. The full list is on the Pralatrexate page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
